Phosphorylated 4E-binding protein 1 (p-4E-BP1): A novel prognostic marker in human astrocytomas

Histopathology

Volumn 61, Issue 2, 2012, Pages 293-305

  Korkolopoulou, Penelope ^a   Levidou, Georgia ^a   El Habr, Elias A ^a   Piperi, Christina ^a   Adamopoulos, Christos ^a   Samaras, Vassilis ^a   Boviatsis, Efstathios ^a   Thymara, Irene ^a   Trigka, Eleni Andriana ^a   Sakellariou, Stratigoula ^a   Kavantzas, Nikolaos ^a   Patsouris, Efstratios ^a   Saetta, Angelica A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Astrocytomas; IDH1 R132H; P 4E BP1; P mTOR; P p70S6K

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; ISOCITRATE DEHYDROGENASE 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RAPAMYCIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BLOTTING, WESTERN; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

MAMMALIA;

EID: 84864390839     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04236.x     Document Type: Article

References (42)

1. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr. Opin. Genet. Dev. 2006; 16; 78-84.
2. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441; 424-430.
3. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18; 1926-1945.
4. Gingras AC, Gygi SP, Raught B et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999; 13; 1422-1437.
5. Ayuso MI, Hernández-Jiménez M, Martín ME, Salinas M, Alcázar A. New hierarchical phosphorylation pathway of the translational repressor eIF4E-binding protein 1 (4E-BP1) in ischemia-reperfusion stress. J. Biol. Chem. 2010; 285; 34355-34363.
6. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23; 3189-3199.
7. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997; 16; 3693-3704.
8. Kremer CL, Klein RR, Mendelson J et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66; 1203-1212.
9. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 2006; 66; 3126-3136.
10. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009; 27; 2278-2287.
11. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005; 17; 596-603.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103; 253-262.
13. Saetta AA, Levidou G, El-Habr EA et al. Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. Virchows Arch. 2011; 458; 749-759.
14. Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010; 120; 707-718.
15. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114; 97-109.
16. Zisakis A, Piperi C, Themistocleous MS et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 2007; 39; 99-105.
17. Capper D, Weissert S, Balss J et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010; 20; 245-254.
18. Rojo F, Najera L, Lirola J et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin. Cancer Res. 2007; 13; 81-89.
19. Castellvi J, Garcia A, Rojo F et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107; 1801-1811.
20. Yeh CJ, Chuang WY, Chao YK et al. High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch. 2011; 458; 171-178.
21. Korkolopoulou P, Patsouris E, Konstantinidou AE et al. Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol. Appl. Neurobiol. 2004; 30; 267-278.
22. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control. Clin. Trials 2000; 21; 552-560.
23. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 2001; 98; 10314-10319.
24. Galanis E, Buckner JC, Maurer MJ et al. North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005; 23; 5294-5304.
25. Rao RD, Mladek AC, Lamont JD et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005; 7; 921-929.
26. Chakravarti A, Zhai G, Suzuki Y et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004; 22; 1926-1933.
27. Choe G, Horvath S, Cloughesy TF et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003; 63; 2742-2746.
28. Pelloski CE, Lin E, Zhang L et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin. Cancer Res. 2006; 12; 3935-3941.
29. Ermoian RP, Kaprealian T, Lamborn KR et al. Signal transduction molecules in gliomas of all grades. J. Neurooncol. 2009; 91; 19-26.
30. Yang J, Liao D, Wang Z, Liu F, Wu G. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis. J. Surg. Res. 2011; 168; 97-102.
31. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. 2006; 66; 5618-5623.
32. Pende M, Um SH, Mieulet V et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 2004; 24; 3112-3124.
33. She QB, Halilovic E, Ye Q et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18; 39-51.
34. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002; 22; 7004-7014.
35. Yu G, Wang J, Chen Y et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin. Cancer Res. 2009; 15; 1821-1829.
36. Braunstein S, Karpisheva K, Pola C et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol. Cell 2007; 28; 501-512.
37. Dubois L, Magagnin MG, Cleven AH et al. Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance. Int. J. Radiat. Oncol. Biol. Phys. 2009; 73; 1219-1227.
38. Benavente S, Vergés R, Hermosilla E et al. Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75; 1316-1322.
39. Darb-Esfahani S, Faggad A, Noske A et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade invivo and link with response to rapamycin treatment invitro. J. Cancer Res. Clin. Oncol. 2009; 135; 933-941.
40. Armengol G, Rojo F, Castellvi J et al. 4E-binding protein 1: a key molecular 'funnel factor' in human cancer with clinical implications. Cancer Res. 2007; 67; 7551-7555.
41. Fan QW, Weiss WA. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr. Top. Microbiol. Immunol. 2010; 347; 279-296.
42. Dumstorf CA, Konicek BW, McNulty AM et al. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis. Mol. Cancer Ther. 2010; 9; 3158-3163.